HC Wainwright Reiterates “Buy” Rating for ZyVersa Therapeutics (NASDAQ:ZVSA)

ZyVersa Therapeutics (NASDAQ:ZVSA)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $12.00 price objective on the stock.

ZyVersa Therapeutics Price Performance

Shares of ZVSA stock opened at $0.78 on Tuesday. The stock has a 50 day simple moving average of $0.73 and a 200-day simple moving average of $2.10. ZyVersa Therapeutics has a 12-month low of $0.50 and a 12-month high of $90.65.

Hedge Funds Weigh In On ZyVersa Therapeutics

A hedge fund recently bought a new stake in ZyVersa Therapeutics stock. Walleye Capital LLC bought a new position in shares of ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 980,568 shares of the company’s stock, valued at approximately $128,000. Walleye Capital LLC owned approximately 3.17% of ZyVersa Therapeutics at the end of the most recent quarter. 3.91% of the stock is currently owned by institutional investors.

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company engages in the development of VAR 200, a cholesterol efflux mediator, which is in Phase 2a clinical trial to the treatment of multiple renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic nephropathy; and IC 100, a monoclonal antibody inflammasome ASC inhibitor that is in preclinical stage for treatment of multitude of inflammatory diseases.